Search
for

    Glossary Sorafenib

    medication that inhibits proteins to slow cancer growth

    Sorafenib is a medication primarily used to treat certain types of cancer, such as liver, kidney, and thyroid cancers. It works by inhibiting multiple proteins involved in tumor cell growth and angiogenesis (the formation of new blood vessels that supply the tumor), thereby slowing the progression of the disease.

    Sort by

    Research 30 of 167

    1. Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis Clinical Cancer Research · 2011 · 215 citations
    2. Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review) Oncology Reports · 2012 · 46 citations
    3. Hand-Foot and Stump Syndrome to Sorafenib Journal of Clinical Oncology · 2007 · 45 citations
    4. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea Frontiers in Endocrinology · 2019 · 39 citations
    5. Sorafenib-induced eruption resembling pityriasis rubra pilaris Journal of the American Academy of Dermatology · 2011 · 21 citations
    6. Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma Archives of Medical Science · 2017 · 16 citations
    7. Sorafenib-Associated Facial Acneiform Eruption Dermatology and therapy · 2014 · 15 citations
    8. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment International Journal of Immunopathology and Pharmacology · 2017 · 14 citations
    9. A distinct cutaneous reaction to sorafenib and a multikinase inhibitor International Journal of Dermatology · 2008 · 13 citations
    10. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib Journal of clinical biochemistry and nutrition · 2016 · 12 citations
    11. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib Clinical and Experimental Dermatology · 2013 · 11 citations
    12. Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib Clinical and translational science · 2016 · 10 citations
    13. Sorafenib stimulates human skin type mast cell degranulation and maturation Journal of dermatological science · 2017 · 7 citations
    14. Delayed onset perforating folliculitis associated with sorafenib Australasian journal of dermatology · 2014 · 5 citations
    15. Case of alopecia induced by sorafenib, possible mechanism similar to alopecia areata The Journal of Dermatology · 2017 · 4 citations
    16. Sorafenib-Induced Pityriasis Rubra Pilaris-like Eruption: A Case Report Indian Dermatology Online Journal · 2025 · 1 citations
    17. Sorafenib-induced Facial Acneiform Eruption Cureus · 2019
    18. Transient perforating folliculitis induced by sorafenib Institutional Repositories DataBase (IRDB) · 2010
    19. Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer Bioscience Journal · 2023 · 1 citations
    20. Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects Current drug metabolism · 2009 · 508 citations
    21. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma Clinical cancer research · 2004 · 234 citations
    22. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer Journal of the American Academy of Dermatology · 2014 · 88 citations
    23. Advances in the Management of Cutaneous Toxicities of Targeted Therapies Seminars in Oncology · 2012 · 42 citations
    24. Skin toxicity of anti‐cancer therapy Journal der Deutschen Dermatologischen Gesellschaft · 2008 · 19 citations
    25. Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female World journal of surgical oncology · 2018 · 4 citations
    26. Adverse Hair Reactions to New Targeted Therapies for Cancer Actas Dermo-Sifiliográficas · 2019 · 1 citations
    27. Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique 2011
    28. Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana Projeto: revista mensal de arquitetura · 2008
    29. Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer Journal of thoracic oncology · 2010 · 12 citations
    30. Efluvio anágeno. Hallazgos tricoscópicos Revista Dermatológica Centro Uraga · 2020